EWS Gene Fusions as Diagnostic Markers in Sarcomas: Principles and Guidelines

Highly specrtic chromosomal translocations are found in several primitive sarcomas (1 –3 ). Biologically, the breakpoints of these translocations involve various putative or confirmed transcription factor genes, some of which appear to participate in normal mesenchymal development and differentiation These genes are rearranged by the translocations, resulting in the formation of chimeric genes, encoding novel tumor-specific transcription factors that are presumed to disrupt normal differentiation and lead to sarcomagenesis. Several lines of evidence suggest that the fusion genes encoded by these translocations are likely to be either necessary or sufficient for sarcomagenesis The area has been the subject of several recent reviews (1 –3 ). Besides their biological significance, these translocations are of great diagnostic interest as tumor markers. The morphological diagnosis of sarcomas is often problematic. The possibility of detecting tumor-type-specific translocations represents an extremely useful diagnostic modality TheEWSgene, located at 22q12, is the single most commonly involved gene in these translocations and thus plays a pivotal role in several different types of sarcomas, including Ewing’s sarcoma, clear cell sarcoma, desmoplastic small round cell tumor, and extraskeletal myxoid chondrosarcoma (seeTable 1 ). We expect that the usefulness ofEWSrearrangements as tumor markers in sarcomas will only continue to grow as additionalEWSgene fusions are identified. Table 1MajorEWSGene Fusions in Sarcomas: RT-PCR Detection

Chromosomal translocatron

Fusion product

EWSforward primera

Reverse primer

Product size (bp)

Internal and fusion Junction probes

Ewmg’s sarcoma/PNET

t(ll.22)(q24,q12)

EWS/FLII

ex 7

FLIIex 9 ACTCCCCGTTGGTCCCCTCC

type1 120

EWS ex 7TATAGCCAACAGAGGAGCAG

type2 183

FL11ex 6 CAAGCTCCTCTTCTGACTGAG

ex 7

FLIIex 6 GITGAGGCCAGAATTCATGTTA

type1 327

EWS/FLIItype1 ACGGGCAGCAGAACCCTTCTTATG

type 2 390

EWS/FLIItype 2 ACGGGCAGCAGAGTTCACTGCTGG

t(21,22)(q22,q12)

EWS/ERG

ex 7

ERG ex 9 AAAGCTGGATCTGGCCACTG

Various

ERGAGTCGAAAGCTGCTCACCATCT

Clear-cell sarcoma (MMSP)

t(l2,22)(q13,q12)

EWS/ATFI

ex 8

ATFITCTCCGTCTCCTTTTCTGC

126

EWS/ATFICGGTGGAATGGGAAAAATTTTGAA

Desmoplastlc SRCT

t(12,22)(pl3,q12)

EWS/WTI

ex 7

WTIex 9 GACCAGGAGAACTTKGCTGAC

197

EWS/WTIACGGGCAGCAGAGTGAGAAACCAT

Extraskeletal myxold CS

t(9,22)(q22,ql2)

EWS/CHN

type 1

ex 12

CHNCCTGGAGGGGAAGGGCTAT

109

EWS/CHNtype 1 AATGGTTTGATGATATGCCCTGCG

type 2

ex 7

CHNCCTGGAGGGGAAGGGCTAT

275

EWSKHNtype 2 ACGGGCAGCAGAAGCCCACTGCGG

aEWS forward primers exon 7 TCCTACAGCCAAGCTCCAAGTC, exen 8 GGGMGAGGGGGATTTGA, exen 12 AAGGCGATGCCACAGTGTC

内容来源:生物资料网,如果侵权麻烦联系网站工作人员删除!

艾美捷科技优势代理品牌

发表评论

:?: :razz: :sad: :evil: :!: :smile: :oops: :grin: :eek: :shock: :???: :cool: :lol: :mad: :twisted: :roll: :wink: :idea: :arrow: :neutral: :cry: :mrgreen: